Literature DB >> 18336525

Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.

Siddhartha Mondragón-Rodríguez1, Gustavo Basurto-Islas, Ismael Santa-Maria, Raúl Mena, Lester I Binder, Jesús Avila, Mark A Smith, George Perry, Francisco García-Sierra.   

Abstract

Phosphorylation, cleavage and conformational changes in tau protein all play pivotal roles during Alzheimer's disease (AD). In an effort to determine the chronological sequence of these changes, in this study, using confocal microscopy, we compared phosphorylation at several sites (Ser(199/202/396/404/422)-Thr(205) and the second repeat domain), cleavage of tau (D(421)) and the canonical conformational Alz-50 epitope. While all of these posttranslational modifications are found in neurofibrillary tangles (NFTs) at all stages of the disease, we found significantly higher numbers of phospho-tau positive NFTs when compared with cleaved tau (P = 0.006 in Braak III; P = 0.002 in Braak IV; P = 0.012 in Braak V) or compared with the Alz-50 epitope (P < 0.05). Consistent with these findings, in a double transgenic mice model (Tet/GSK-3beta/VLW) overexpressing the enzyme glycogen synthase kinase-3beta (GSK-3beta) and tau with a triple FTDP-17 mutation (VLW) with AD-like neurodegeneration, phosphorylation at sites Ser(199/202)-Thr(205) was greater than truncated tau. Taken together, these data strongly support the notion that the conformational changes and truncation of tau occur after the phosphorylation of tau. We propose two probable pathways for the pathological processing of tau protein during AD, either phosphorylation and cleavage of tau followed by the Alz-50 conformational change or phosphorylation followed by the conformational change and cleavage as the last step.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336525      PMCID: PMC2525766          DOI: 10.1111/j.1365-2613.2007.00568.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  48 in total

1.  Abortive apoptosis in Alzheimer's disease.

Authors:  A K Raina; A Hochman; X Zhu; C A Rottkamp; A Nunomura; S L Siedlak; H Boux; R J Castellani; G Perry; M A Smith
Journal:  Acta Neuropathol       Date:  2001-04       Impact factor: 17.088

2.  Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.

Authors:  Tobias Engel; Félix Hernández; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2006-05-10       Impact factor: 6.167

Review 3.  Apoptosis in Alzheimer disease: a mathematical improbability.

Authors:  Xiongwei Zhu; Arun K Raina; George Perry; Mark A Smith
Journal:  Curr Alzheimer Res       Date:  2006-09       Impact factor: 3.498

4.  Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation.

Authors:  T Timm; D Matenia; X-Y Li; B Griesshaber; E-M Mandelkow
Journal:  Neurodegener Dis       Date:  2006       Impact factor: 2.977

5.  Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels.

Authors:  Toshifumi Matsui; Karunya Ramasamy; Martin Ingelsson; Hiroaki Fukumoto; Cintia Conrad; Matthew P Frosch; Michael C Irizarry; Junying Yuan; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2006-05       Impact factor: 3.685

6.  Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

Authors:  Tobias Engel; Paloma Goñi-Oliver; José J Lucas; Jesús Avila; Félix Hernández
Journal:  J Neurochem       Date:  2006-10-24       Impact factor: 5.372

7.  Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration.

Authors:  Tobias Engel; José J Lucas; Pilar Gómez-Ramos; María A Moran; Jesús Avila; Félix Hernández
Journal:  Neurobiol Aging       Date:  2005-07-27       Impact factor: 4.673

8.  Tau-66: evidence for a novel tau conformation in Alzheimer's disease.

Authors:  N Ghoshal; F García-Sierra; Y Fu; L A Beckett; E J Mufson; J Kuret; R W Berry; L I Binder
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

9.  Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments.

Authors:  A Alonso ; T Zaidi; M Novak; I Grundke-Iqbal; K Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

10.  Expression of embryonic tau protein isoforms persist during adult neurogenesis in the hippocampus.

Authors:  Torsten Bullmann; Rohan de Silva; Max Holzer; Hiroshi Mori; Thomas Arendt
Journal:  Hippocampus       Date:  2007       Impact factor: 3.899

View more
  46 in total

1.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

Review 2.  Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Hyoung-gon Lee; George Perry; Xiongwei Zhu; Rudy J Castellani; Mark A Smith
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Authors:  Patrick Reilly; Charisse N Winston; Kelsey R Baron; Margarita Trejo; Edward M Rockenstein; Johnny C Akers; Najla Kfoury; Marc Diamond; Eliezer Masliah; Robert A Rissman; Shauna H Yuan
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

Review 4.  The physical chemistry of brain and neural cell membranes: an overview.

Authors:  D S Robertson
Journal:  Neurochem Res       Date:  2010-01-22       Impact factor: 3.996

5.  Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Authors:  David J Irwin; Todd J Cohen; Murray Grossman; Steven E Arnold; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

6.  Flavanols, mild cognitive impairment, and Alzheimer's dementia.

Authors:  Ami K Patel; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Med       Date:  2008-04-15

7.  Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; Eva L Feldman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Memantine prevents sensitivity to excitotoxic cell death of rat cortical neurons expressing human truncated tau protein.

Authors:  Martin Cente; Stanislava Mandakova; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2009-03-17       Impact factor: 5.046

9.  A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation.

Authors:  Deepa Ajit; Hanna Trzeciakiewicz; Jui-Heng Tseng; Connor M Wander; Youjun Chen; Aditi Ajit; Diamond P King; Todd J Cohen
Journal:  J Biol Chem       Date:  2019-09-22       Impact factor: 5.157

10.  The tau code.

Authors:  Jesús Avila
Journal:  Front Aging Neurosci       Date:  2009-07-30       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.